Myelofibrosis is a rare and chronic bone marrow disorder characterized by the abnormal production of blood cells and the development of fibrous tissue in the bone marrow. It is also known as agnogenic myeloid metaplasia or idiopathic myelofibrosis. This condition belongs to a group of diseases called myeloproliferative neoplasms, which involve the overproduction of blood cells.
Myelofibrosis is a progressive disease that primarily affects individuals over the age of 50, although it can occur at any age. The exact cause of myelofibrosis is still unknown, but it is believed to be related to genetic mutations in the bone marrow cells. These mutations lead to the abnormal production of blood cells, including red blood cells, white blood cells, and platelets.
The symptoms of myelofibrosis can vary from person to person, but commonly include fatigue, shortness of breath, enlarged spleen, night sweats, unexplained weight loss, and bone pain. As the disease progresses, it can lead to complications such as anemia, increased susceptibility to infections, and bleeding disorders.
Diagnosis of myelofibrosis involves a combination of medical history evaluation, physical examination, blood tests, bone marrow biopsy, and genetic testing. Treatment options for myelofibrosis aim to manage symptoms, improve quality of life, and slow down the progression of the disease. These may include medications to reduce symptoms and complications, blood transfusions to manage anemia, stem cell transplantation for eligible patients, and supportive care to address specific symptoms and complications.
Living with myelofibrosis requires ongoing medical monitoring and management. It is important for individuals with myelofibrosis to work closely with their healthcare team to develop an individualized treatment plan and to address any concerns or questions they may have.